Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2

S. Farschtschi; V. L. Merker; D. Wolf; M. Schuhmann; J. Blakeley; S. R. Plotkin; C. Hagel; V. F. Mautner

doi:10.1111/ane.12490

journal article Sep 15, 2015

Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2

S. Farschtschi V. L. Merker D. Wolf M. Schuhmann J. Blakeley S. R. Plotkin C. Hagel V. F. Mautner

Acta Neurologica Scandinavica Vol. 133 No. 6 pp. 475-480 · Hindawi Limited

View at Publisher Save 10.1111/ane.12490

Topics

No keywords indexed for this article. Browse by subject →

References

15

[1]

Evans "Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought" Otol Neurotol (2005) 10.1097/00129492-200501000-00016

[2]

Mautner "The neuroimaging and clinical spectrum of neurofibromatosis 2" Neurosurgery (1996) 10.1097/00006123-199605000-00004

[3]

Mautner "Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety" AJR Am J Roentgenol (1995) 10.2214/ajr.165.4.7676998

[4]

Plotkin "Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients" J Neurosurg Spine (2011) 10.3171/2010.11.spine10350

[5]

Hagel "Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas" Neuropathology (2012) 10.1111/j.1440-1789.2012.01306.x

[6]

Lee "Long-term outcomes of surgical resection with or without adjuvant radiation therapy for treatment of spinal ependymoma: a retrospective multicenter study by the Korea Spinal Oncology Research Group" Neuro Oncol (2013) 10.1093/neuonc/not038

[7]

Epstein "Adult intramedullary spinal cord ependymomas: the result of surgery in 38 patients" J Neurosurg (1993) 10.3171/jns.1993.79.2.0204

[8]

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

Scott R. Plotkin, Anat O. Stemmer-Rachamimov, Fred G. Barker et al.

New England Journal of Medicine 2009 10.1056/nejmoa0902579

[9]

Plotkin "Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients" Otol Neurotol (2012) 10.1097/mao.0b013e31825e73f5

[10]

Jain "Antiangiogenic therapy for cancer: current and emerging concepts" Oncology (Williston Park) (2005)

[11]

Green "Bevacizumab for recurrent ependymoma" Neurology (2009) 10.1212/wnl.0b013e3181c1df34

[12]

Gururangan "Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma-a Pediatric Brain Tumor Consortium study" Neuro Oncol (2012) 10.1093/neuonc/nos213

[13]

Mautner "Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2" Neuro Oncol (2010) 10.1093/neuonc/nop010

[14]

Bent "Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas" Lancet Oncol (2011) 10.1016/s1470-2045(11)70057-2

[15]

Chan "Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma" Am J Surg Pathol (1998) 10.1097/00000478-199807000-00004

Cited By

47

Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons

D. Bradley Welling · 2023

Otolaryngologic Clinics of North Am...

Bevacizumab as a surgery-sparing agent for spinal ependymoma in patients with neurofibromatosis type II: Systematic review and case

M. Harrison Snyder, Leonel Ampie · 2021

Journal of Clinical Neuroscience

The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2

Katrina A. Morris, Shazia K. Afridi · 2017

Journal of Neurosurgery: Spine

Metrics

47

Citations

15

References

Details

Published: Sep 15, 2015
Vol/Issue: 133(6)
Pages: 475-480
License: View

Authors

S

S. Farschtschi

Department of Neurology; University Medical Center Hamburg-Eppendorf; Hamburg Germany

V

V. L. Merker

Massachusetts General Hospital; Pappas Center for Neuro Oncology; Boston MA USA

D

D. Wolf

Department of Neurology; The Johns Hopkins Hospital; Baltimore MD USA

M

M. Schuhmann

Department of Neurosurgery; University Medical Center Tübingen; Tübingen Germany

J

J. Blakeley

Department of Neurology; The Johns Hopkins Hospital; Baltimore MD USA

S

S. R. Plotkin

Massachusetts General Hospital; Pappas Center for Neuro Oncology; Boston MA USA

C

C. Hagel

Institute of Neuropathology; University Medical Center Hamburg-Eppendorf; Hamburg Germany

V

V. F. Mautner

Department of Neurology; University Medical Center Hamburg-Eppendorf; Hamburg Germany

Cite This Article

S. Farschtschi, V. L. Merker, D. Wolf, et al. (2015). Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurologica Scandinavica, 133(6), 475-480. https://doi.org/10.1111/ane.12490

Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2

You May Also Like